| HEART FAILURE IN PATIENTS WITH SARCOPENIA: SYSTEMATIC REVIEW AND META-ANALYSIS |
Pedro Ivo Carmo Campos1 
, Marcus Vinicius Bolivar Malachias2, Amanda Aparecida Oliveira Leopoldino3, Juliano Bergamaschine Mata Diz4 |
1Postgraduation Department, Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
2Faculdade Ciências Médicas de Minas Gerais, Fundação Educacinoal Lucas Machado, Belo Horizonte, Minas Gerais, Brazil
3Department of Physical Therapy, Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
4Faculdade de Medicina de Barbacena, Barbacena, Minas Gerais, Brazil |
Correspondence:
Pedro Ivo Carmo Campos,
Email: pivocampos@gmail.com
|
|
Received: 9 December 2024 • Revised: 2 March 2025 • Accepted: 31 March 2025 |
| Abstract |
Introduction: The prevalence of sarcopenia and heart failure (HF) is estimated to be between 8% – 34% and 3% – 11.8%, respectively. The prevalence of HF in patients with sarcopenia and the prognosis of this association remain unclear.
Methods
A systematic review was conducted across MEDLINE/PubMed, Embase, CENTRAL, Scielo, and CINAHL databases, with manual searches in Google Scholar and grey literature. Meta-analysis was performed on the gathered results to assess the prevalence of HF in patients with sarcopenia, estimate phenotypes related to left ventricular ejection fraction (LVEF), and evaluate the associated mortality risk.
Results
Out of 7.080 studies, 16 were selected. In patients with sarcopenia HF prevalence was 32% (95% CI 0.07–0.61, p<0.001, I²=100%). Patients with both conditions showed 45.9% (95% CI 0.34 – 0.58, p<0.001, I² 90.69%) with reduced LVEF, 10.3% (95% CI 0.00 – 0.29, p<0.001, I² 99%) with mildly reduced LVEF, and 29.1% (95% CI 0.14 – 0.45, p<0.001, I² 99%) having preserved LVEF.
Conclusion
HF is highly prevalent in patients with sarcopenia and increases mortality risk.
|
| Key Words:
Heart failure, sarcopenia, epidemiology, prevalence, ejection fraction |
|
PDF Links
Full text via DOI
Download Citation
